Breast cancer

TOPOLOGY

A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.

Open at Paris since : 29/02/2024
Open at Saint-Cloud since : 14/02/2024
Target : Adult
Phase : Phase II

Trial description

Efficacy of PLX038 on response rate.;Primary endpoint:;Best tumor response (defined as PR or CR in the first 6 months of treatment, assessed by investigators per RECIST v1.1 criteria).

Url of the trial

Main investigator

FRANCOIS-CLEMENT BIDARD

Professeur - Médecin

Contact